Synopsis: As 2026 begins, investors are shifting focus toward companies aligned with long-term structural themes such as data centres, AI infrastructure, healthcare devices, premium consumption, real estate redevelopment, and specialty manufacturing. This curated list highlights high-quality businesses with strong execution, durable competitive advantages, and multi-year growth visibility shaping portfolio opportunities ahead.
2026 has begun and investors are increasingly looking beyond short-term noise and focusing on businesses riding long structural trends. From data centres and AI infrastructure to luxury consumption, healthcare devices, real estate redevelopment, and premium chemicals, these themes reflect where capital, demand, and profitability are steadily converging.
The following companies operate at the intersection of these shifts, combining strong execution with multi-year growth drivers that could shape portfolio performance in the years ahead.
Privi Speciality Chemicals
Founded in 1985, Privi Speciality Chemicals is a leading manufacturer and exporter of aroma and fragrance chemicals used across FMCG and fine fragrance applications. The company caters to global customers with a strong focus on scale, consistency, and customisation. The stock trades at Rs. 2,695.55 with a market capitalisation of Rs. 10,529.55 crore.
Privi produces a wide range of aroma chemicals across over 20 categories, including phenol derivatives, pine chemicals like alpha-pinene and beta-pinene, and musk products. These ingredients are core building blocks for perfumes, soaps, detergents, shampoos, insect repellents, candles, and other consumer products used worldwide.
Over the last three years, Privi has delivered a profit CAGR of 26 percent and a sales CAGR of 14 percent. The stock currently trades at a PE of 39.4 times, compared to an industry average of 27.5 times, reflecting its superior integration and global positioning.
Privi’s biggest edge lies in its backward integration through CST, a pine-based by-product sourced from over 60 global pulp mills, offering a 15-20 percent cost advantage over volatile GTO. It is the only Asian company among just four globally capable of processing CST at scale, enabled by its sulphur-removal technology and dedicated refinery commissioned in 2016.
With the flexibility to switch between CST and GTO based on cost dynamics, Privi remains the lowest-cost producer globally. Its stable pricing, deep relationships with clients like Givaudan, Firmenich, IFF, P&G, and Henkel, and leadership in multiple molecules with over 20 percent global share position it strongly for sustained growth in 2026.
Shaily Engineering Plastics
Shaily Engineering Plastics manufactures precision injection-moulded plastic components and sub-assemblies for global OEMs across multiple industries. With exports to nearly 40 countries, the company has built strong capabilities in high-precision manufacturing. The stock is priced at Rs. 2,229.60 with a market capitalisation of Rs. 10,246.15 crore.
Shaily’s portfolio spans pharmaceutical delivery devices such as insulin pens, inhalers, and auto-injectors, along with specialty packaging and contract manufacturing. It also produces plastic components for personal care, appliances, automotive, lighting, furniture, and consumer kitchen products.
The company has delivered a strong profit CAGR of 38 percent and a sales CAGR of 11 percent over the past three years. The stock trades at a PE of 70 times, significantly higher than the industry average of 22.6 times, reflecting expectations of healthcare-led growth.
Shaily is emerging as a key beneficiary of the fast-expanding GLP-1 drug ecosystem. The global anti-obesity drug market is expected to grow from USD 13.84 billion in 2024 to nearly USD 49 billion by 2030, while India’s GLP-1 market is projected to compound at over 34 percent annually. Shaily designs and manufactures plastic pens used for semaglutide delivery and counts Dr. Reddy’s Laboratories among its key clients.
Its healthcare segment doubled its revenue share to 31 percent in Q1 FY26, driven by rising demand for injection devices. With a narrow window before generics enter India, device suppliers like Shaily are well placed to capture volume-led growth through 2026.
TD Power Systems
TD Power Systems designs and manufactures customised AC generators and electric motors for industrial, power, and infrastructure applications, with installations across more than 110 countries. The company has established a strong global footprint in large rotating electrical equipment. The stock trades at Rs. 672.60 with a market cap of Rs. 10,507.01 crore.
TDPS manufactures generators ranging from 1 to 250 MVA for steam, gas, hydro, wind turbines, and engines, along with synchronous and induction motors for industrial and irrigation use. It also supplies traction motors for rail and transit systems, reflecting deep engineering capabilities.
Over the past three years, TDPS has reported a profit CAGR of 39 percent and a sales CAGR of 17 percent. The stock trades at a PE of 50.3 times versus an industry PE of 44.1 times, indicating optimism around future order inflows.
The rapid expansion of global data centres, driven by AI and cloud workloads, is a major tailwind for TDPS. With Morgan Stanley estimating nearly USD 3 trillion in global data centre investments by 2029, demand for reliable power solutions is accelerating. TDPS has secured multiple gas turbine generator orders from US and European OEMs for data centre projects and has completed key system integration tests for high-capacity generators.
Repeat orders, including 44 units of 4.5 MW generators from a German OEM and expected follow-on orders for US data centres in FY26, reinforce its positioning as a critical supplier in this fast-growing segment.
Netweb Technologies India
Founded in 1999, Netweb Technologies is India’s leading provider of high-end computing systems with end-to-end design and manufacturing capabilities. The company operates across HPC, AI, and data centre infrastructure solutions. The stock trades at Rs. 3,313 with a market capitalisation of Rs. 18,769.43 crore.
Netweb delivers high-performance computing systems, AI and GPU-based solutions, private cloud and hyperconverged infrastructure, enterprise workstations, data centre servers, and high-performance storage, supported by in-house manufacturing and nationwide service capabilities.
Netweb has delivered exceptional growth, with a three-year profit CAGR of 72 percent and a sales CAGR of 67 percent. The stock trades at a PE of 139 times, well above the industry average of 31 times, reflecting its niche leadership and growth runway.
Netweb is uniquely positioned as India’s only HPC OEM, having delivered multiple supercomputers featured in the global Top 500 list and India’s flagship AI supercomputer. Its AI systems business has grown at a 91 percent revenue CAGR over four years, supported by AI spending in India projected to grow at over 31 percent annually till 2027.
Strategic OEM access to Nvidia, enjoyed by fewer than 10 companies globally, ensures priority GPU allocation. With EBITDA margins guided at 13-14 percent and exports targeted at 5-6 percent of revenue, Netweb stands at the centre of India’s AI and data centre buildout heading into 2026.
Sri Lotus Developers & Realty
Sri Lotus Developers & Realty is a Mumbai-based real estate developer focused on luxury residential and premium commercial redevelopment projects, primarily in the city’s western suburbs. Incorporated in 2015, the company specialises in high-value urban renewal. The stock trades at Rs. 157.10 with a market cap of Rs. 7,677.85 crore.
The company develops luxury and ultra-luxury residential projects through redevelopment partnerships in prime micro-markets such as Bandra, Juhu, Worli, Prabhadevi, Versova, and Nepean Sea Road, catering to high-net-worth buyers.
Sri Lotus has delivered a three-year profit CAGR of 207 percent and a sales CAGR of 84 percent. The stock trades at a PE of 34.4 times, broadly in line with the industry average of 34.1 times.
Mumbai’s redevelopment story is structural, not cyclical. Over 70 percent of developable land under MCGM is already built up, while population density exceeds 30,000 people per sq km, leaving redevelopment as the primary source of new supply. Sri Lotus focuses exclusively on premium micro-markets where pricing power is strongest and execution risks are lower.
As ageing buildings are replaced with modern high-rise developments, redevelopment is becoming essential for urban efficiency. With luxury demand remaining resilient and land scarcity intensifying, Sri Lotus is well placed to benefit from Mumbai’s long-term urban transformation through 2026 and beyond.
Sona BLW Precision Forgings
Sona BLW Precision Forgings is a global automotive technology company supplying engineered systems and components to mobility OEMs across EV, hybrid, ICE, and rail segments. The company has built strong capabilities in precision engineering and electrification. The stock trades at Rs. 459.95 with a market capitalisation of Rs. 28,596.06 crore.
Sona designs and manufactures driveline systems, traction motors, and differential assemblies for EVs and hybrids, along with components for railways and conventional vehicles. Its capabilities span mechanical, electrical, and software-led automotive systems.
Over the last three years, Sona BLW has posted a profit CAGR of 19 percent and a sales CAGR of 19 percent. The stock trades at a PE of 45.6 times compared to an industry PE of 30.4 times.
While recent quarters have seen pressure, Sona’s long-term drivers remain intact. Hybrid motors already contribute 24 percent of automotive revenue and offer higher value per vehicle. The company has demonstrated agility by adapting motor designs following rare earth supply disruptions within months. Beyond EVs, investments in robotics, cobots, and new driveline products expand optionality over a 5-10 year horizon.
Continuous process optimisation, cost efficiency initiatives, and diversification across products and geographies suggest that near-term challenges are manageable, keeping the long-term growth story intact into 2026.
Varun Beverages
Varun Beverages is one of the largest global franchisees of PepsiCo, engaged in manufacturing and distributing beverages and snacks across India and international markets. The company has built scale through aggressive expansion and execution. The stock trades at Rs. 488.85 with a market cap of Rs. 1,65,328.52 crore.
Varun Beverages produces and distributes Pepsi, Mountain Dew, 7UP, Mirinda, Sting, Aquafina, Gatorade, Lipton Ice Tea, and snack brands like Lays, Cheetos, Doritos, and Kurkure Puffcorn, along with select in-house brands and dairy beverages.
The company has delivered a profit CAGR of 55 percent and a sales CAGR of 31 percent over three years. The stock trades at a PE of 56 times versus an industry PE of 49.4 times.
The acquisition of South Africa-based Twizza (manufactures and distributes non-alcoholic beverages), with annual capacity of nearly 100 million cases, strengthens Varun’s African footprint and diversifies revenue streams. The deal, valued at around Rs. 1,118 crore, supports backward integration and supply chain control. Combined with improving domestic demand, expanding distribution in emerging markets, and strong execution in energy drinks and snacks, Varun Beverages is well positioned to sustain high growth rates and margin expansion through 2026.
Ethos
Ethos is India’s largest luxury and premium watch retailer, operating as a pure-play curated retailer rather than a manufacturer. It focuses on experience-led luxury consumption across physical and digital platforms. The stock trades at Rs. 2,823.30 with a market capitalisation of Rs. 7,554.50 crore.
Ethos retails over 80 global luxury watch brands through 83 stores across 26 cities, offering new and certified pre-owned watches via its Second Movement platform, along with personalised advisory and after-sales services.
Ethos has delivered a three-year profit CAGR of 60 percent and a sales CAGR of 29 percent. The stock trades at a PE of 79.2 times, significantly above the industry average of 26.9 times.
India’s luxury market is projected to grow from USD 17.7 billion in 2024 to over USD 85 billion by 2030, supported by rising incomes and aspirational consumption. Ethos benefits uniquely from exposure to both new and pre-owned luxury watches, a segment expected to reach USD 29-32 billion globally by 2025.
With 32 percent of consumers planning to buy pre-owned luxury watches and Ethos offering certified refurbishment with warranties, the company stands to capture a disproportionate share of India’s luxury watch demand in 2026.
Radico Khaitan
Radico Khaitan is one of India’s oldest liquor companies, having evolved from a bulk spirits player into a premium-focused IMFL brand owner with strong consumer recall. The stock trades at Rs. 2,949.90 with a market capitalisation of Rs. 39,497.24 crore.
Radico’s portfolio includes premium and luxury brands such as Rampur Single Malt, Jaisalmer Gin, Magic Moments Vodka, Kohinoor Reserve Rum, and multiple whisky variants, catering to India’s premiumising alcohol market.
Over three years, Radico has posted a profit CAGR of 10 percent and a sales CAGR of 19 percent. The stock trades at a PE of 84.9 times, compared to an industry PE of 39.4 times.
India’s shift toward premium alcohol is driving margin expansion across the sector. Radico is benefiting from premiumisation, wider distribution in Tier-2 and Tier-3 cities, and brand-led growth. JM Financial expects an 18 percent net sales CAGR and 24 percent CAGR in the premium and above segment between FY25 and FY28, with margins expanding by around 200 basis points. Strategic partnerships and leadership in vodka, where Radico holds over 60 percent market share, position it strongly for sustained premium-led growth into 2026.
Rubicon Research
Founded in 1999, Rubicon Research is a specialty pharmaceutical company focused on complex formulations and drug-device combinations, primarily for regulated markets like the US. The stock trades at Rs. 649.55 with a market cap of Rs. 10,701.36 crore.
Rubicon develops and commercialises specialty generics, nasal sprays, oral solids, liquids, and drug-device combination products, supported by in-house R&D, manufacturing, and front-end market presence in the US.
Rubicon has emerged as one of the fastest-growing pharma companies globally, with an 81 percent revenue CAGR over FY23–25 and an 86 percent commercialization rate in the US. It has 72 active ANDAs and 9 NDAs, with 70 products already launched. Strong pricing discipline, average unit price increases of 8 percent, and leadership in niche products such as Fluticasone nasal sprays support profitability. A spotless USFDA compliance record and growing presence in drug-device combinations position Rubicon as a high-quality growth compounder heading into 2026.
Disclaimer: The views and investment tips expressed by investment experts/broking houses/rating agencies on tradebrains.in are their own, and not that of the website or its management. Investing in equities poses a risk of financial losses. Investors must therefore exercise due caution while investing or trading in stocks. Trade Brains Technologies Private Limited or the author are not liable for any losses caused as a result of the decision based on this article. Please consult your investment advisor before investing.
The post Stocks for 2026: Ethos, Radico Khaitan and 8 other stocks to add to your portfolio appeared first on Trade Brains.